92 related articles for article (PubMed ID: 22335577)
1. An iron regulatory gene signature in breast cancer: more than a prognostic genetic profile?
Nicolini A; Ferrari P; Fallahi P; Antonelli A
Future Oncol; 2012 Feb; 8(2):131-4. PubMed ID: 22335577
[TBL] [Abstract][Full Text] [Related]
2. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX.
Kaklamani V
Expert Rev Mol Diagn; 2006 Nov; 6(6):803-9. PubMed ID: 17140367
[TBL] [Abstract][Full Text] [Related]
3. An iron regulatory gene signature predicts outcome in breast cancer.
Miller LD; Coffman LG; Chou JW; Black MA; Bergh J; D'Agostino R; Torti SV; Torti FM
Cancer Res; 2011 Nov; 71(21):6728-37. PubMed ID: 21875943
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling assays in breast cancer: are we ready for prime time?
Gökmen-Polar Y; Badve S
Oncology (Williston Park); 2012 Apr; 26(4):350-7, 361. PubMed ID: 22655528
[TBL] [Abstract][Full Text] [Related]
5. Is gene array testing to be considered routine now?
Paik S
Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
[TBL] [Abstract][Full Text] [Related]
6. [Molecular portrait of breast cancer with sub-classification of breast tumor].
Siegelmann-Danieli N; Stein ME; Wallach N
Harefuah; 2007 Jan; 146(1):48-52, 77-8. PubMed ID: 17294849
[TBL] [Abstract][Full Text] [Related]
7. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
8. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS
Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
Yang M; Rajan S; Issa AM
Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
[TBL] [Abstract][Full Text] [Related]
10. Molecular predictors of response to therapy for breast cancer.
Galanina N; Bossuyt V; Harris LN
Cancer J; 2011; 17(2):96-103. PubMed ID: 21427553
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.
Bosch A; Eroles P; Zaragoza R; Viña JR; Lluch A
Cancer Treat Rev; 2010 May; 36(3):206-15. PubMed ID: 20060649
[TBL] [Abstract][Full Text] [Related]
12. Personalized medicine: the road ahead.
Mehta R; Jain RK; Badve S
Clin Breast Cancer; 2011 Mar; 11(1):20-6. PubMed ID: 21421518
[TBL] [Abstract][Full Text] [Related]
13. A gene expression signature identifies two prognostic subgroups of basal breast cancer.
Sabatier R; Finetti P; Cervera N; Lambaudie E; Esterni B; Mamessier E; Tallet A; Chabannon C; Extra JM; Jacquemier J; Viens P; Birnbaum D; Bertucci F
Breast Cancer Res Treat; 2011 Apr; 126(2):407-20. PubMed ID: 20490655
[TBL] [Abstract][Full Text] [Related]
14. Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks.
Roukos DH; Ziogas DE; Katsios C
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1187-95. PubMed ID: 20735306
[TBL] [Abstract][Full Text] [Related]
15. Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.
Vuaroqueaux V; Urban P; Labuhn M; Delorenzi M; Wirapati P; Benz CC; Flury R; Dieterich H; Spyratos F; Eppenberger U; Eppenberger-Castori S
Breast Cancer Res; 2007; 9(3):R33. PubMed ID: 17535433
[TBL] [Abstract][Full Text] [Related]
16. Commercialized multigene predictors of clinical outcome for breast cancer.
Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
[TBL] [Abstract][Full Text] [Related]
17. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
18. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
19. [Gene expression based multigene prognostic and predictive tests in breast cancer].
Pénzváltó Z; Mihály Z; Gyorffy B
Magy Onkol; 2009 Dec; 53(4):351-9. PubMed ID: 20071307
[TBL] [Abstract][Full Text] [Related]
20. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
